BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12376811)

  • 21. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
    Leavey PJ; Mantadakis E; Maale G
    Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure].
    von Poblozki A; Dempke W; Schmoll HJ
    Med Klin (Munich); 2000 Aug; 95(8):457-60. PubMed ID: 10985069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucarpidase following high-dose methotrexate: update on development.
    Patterson DM; Lee SM
    Expert Opin Biol Ther; 2010 Jan; 10(1):105-11. PubMed ID: 19925307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.
    Estève MA; Devictor-Pierre B; Galy G; André N; Coze C; Lacarelle B; Bernard JL; Monjanel-Mouterde S
    Eur J Clin Pharmacol; 2007 Jan; 63(1):39-42. PubMed ID: 17115148
    [No Abstract]   [Full Text] [Related]  

  • 26. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commentary.
    Milone MC
    Clin Chem; 2010 Dec; 56(12):1795-6. PubMed ID: 21119036
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
    Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
    Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Commentary.
    Fox E; Balis FM
    Clin Chem; 2010 Dec; 56(12):1795. PubMed ID: 21119037
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
    Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate].
    Yamada K; Takahashi M; Yoshida M
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
    Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
    Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late-onset delayed excretion of methotrexate.
    Pauley JL; Panetta JC; Schmidt J; Kornegay N; Relling MV; Pui CH
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):146-52. PubMed ID: 15148625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Compatibility and toxicity of methotrexate in the treatment of bone tumors].
    Pongracz N; Kelaridis T; Ritschl P
    Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels.
    Wyatt KD; Cooper J; Scott K; Broomall E; Altaf S; Hogan MC; Rodriguez V; Khan S
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):152-155. PubMed ID: 29240024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.
    Widemann BC; Balis FM; Shalabi A; Boron M; O'Brien M; Cole DE; Jayaprakash N; Ivy P; Castle V; Muraszko K; Moertel CL; Trueworthy R; Hermann RC; Moussa A; Hinton S; Reaman G; Poplack D; Adamson PC
    J Natl Cancer Inst; 2004 Oct; 96(20):1557-9. PubMed ID: 15494606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
    Berrak SG; Pearson M; Berberoğlu S; Ilhan IE; Jaffe N
    Pediatr Blood Cancer; 2005 Mar; 44(3):215-9. PubMed ID: 15503294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.